The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Researchers have identified potential concerns with oral semaglutide after an animal study showed biological changes from non-active formulation components. Unlike injections such as Ozempic or Wegovy, pills use excipients and absorption enhancers that may introduce unintended effects. This early warning calls for further human evaluation.
Katy Perry's noticeable weight loss transformation starting in 2023 has fans speculating about Ozempic use, even as she credits diet and hydration. Online chatter about 'Ozempic face' intensified after her 2024 performances and social media posts. Despite denials from Perry and sources, rumors persist into 2025.
Healthify, built on coaching, stands at the cusp of transformation as GLP-1 drugs like semaglutide prepare for patent expiry in India by 2026. Deloitte India's Srikanth Mahadevan forecasts 120,000-150,000 incremental patients in diabetes and weight management. This shift could make premium therapies accessible, fueling coaching platforms' growth.
Wegovy's explosion on TikTok and US headlines promises dramatic weight loss, but the reality involves high costs, pharmacy shortages, and the need for medical supervision. As a higher-dose semaglutide GLP-1 agonist approved for obesity, it offers double-digit weight loss in trials—but stopping it often leads to regain. US experts urge viewing it as chronic disease management, not a casual 'slimming trend.'
A groundbreaking study from Adelaide University is raising questions about SNAC, the ingredient making oral weight-loss drugs like semaglutide tablets viable. In a 21-day animal model, repeated SNAC exposure linked to lower beneficial gut bacteria, reduced protective compounds, and elevated inflammation markers. As tablet versions gain popularity, experts call for more research on this component's full impact.
The weight-loss drug Mounjaro's active ingredient, tirzepatide, is showing promise beyond metabolic health by slashing alcohol intake in animal models. A new study from the University of Gothenburg found it reduced voluntary consumption by over 50%, curbed binge drinking, and prevented relapse. This could signal a new avenue for treating alcohol use disorder through GLP-1/GIP receptor agonism.
Stepping into Thorne's vast supplement factory, the scent of mixed berries hits like childhood nostalgia amid pallets of creatine and berberine. As the industry explodes to $100-200B globally, with 75% of US adults now supplementing, doctors warn of risks in this unregulated minefield. Inside, rigorous testing sets Thorne apart—but is it enough?
Silicon Valley's biohacking craze has hit Temu, where peptides are sold for pennies, raising alarms about safety and purity. From BPC-157 vials to questionable GLP-1s, these products bypass rigorous testing. A closer look reveals why this mainstream shift could be disastrous for health.
A 33-year-old GP tried Mounjaro for obesity and was stunned by more than just weight loss—his 'food noise' vanished, alcohol interest dropped, and mood stabilized. After shedding almost two stone in three months, urges returned upon stopping, highlighting obesity's chronic nature. Now back on 5mg, he emphasizes long-term strategies beyond medication.
